Marian Nakada
Direktor/Vorstandsmitglied bei Vascular Pharmaceuticals, Inc.
Profil
Marian Nakada is currently a Director at Navitor Pharmaceuticals, Inc., ONL Therapeutics, Inc., New England Venture Capital Association, Inc., Vascular Pharmaceuticals, Inc., Padlock Therapeutics, Inc., Aliada Therapeutics, Inc., Ribon Therapeutics, Inc., and Convergence Forum LLC.
Dr. Nakada is also a Board Member at Ribon Therapeutics, Inc. Dr. Nakada previously worked as a Senior Director-Business Development at Centocor Johnson & Johnson from 2006 to 2009.
Dr. Nakada also held positions as a Director at CoStim Pharmaceuticals, Inc., Artizan Biosciences, Inc., and Redona Therapeutics, Inc. Dr. Nakada was a Scientist at Centocor, Inc. Dr. Nakada served as the Strategy, Operations & External Innovation Lead at Janssen, Inc. from 2009 to 2013.
Dr. Nakada received an undergraduate degree from Harvard University in 1983 and a doctorate degree from the University of Pennsylvania in 1999.
Aktive Positionen von Marian Nakada
| Unternehmen | Position | Beginn |
|---|---|---|
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Private Equity Investor | 01.01.2013 |
Vascular Pharmaceuticals, Inc.
 Vascular Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vascular Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of diabetics. It provides new treatment options to individuals living with diabetic complications such as nephropathy. The company was founded by David R. Clemmons and Laura Maile in 2005 and is headquartered in Research Triangle Park, NC. | Direktor/Vorstandsmitglied | - |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - |
Navitor Pharmaceuticals, Inc.
 Navitor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - |
New England Venture Capital Association, Inc.
 New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 10.01.2017 |
ONL Therapeutics, Inc.
 ONL Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ONL Therapeutics, Inc. develops biopharmaceutical services. It protects and improves the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration. The company was founded by David Zacks and Jeffery Jamison in 2006 and is headquartered in Ann Arbor, MI. | Direktor/Vorstandsmitglied | - |
Ribon Therapeutics, Inc.
 Ribon Therapeutics, Inc. BiotechnologyHealth Technology Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA. | Direktor/Vorstandsmitglied | 01.07.2020 |
Aliada Therapeutics, Inc.
 Aliada Therapeutics, Inc. BiotechnologyHealth Technology Aliada Therapeutics, Inc. is a neuroscience-focused company that aims to overcome the delivery hurdle in large molecule drug development. The company is based in Boston, MA. The company is advancing a generation of CNS therapeutics using its novel BBB crossing platform technology, which can efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness. Aliada Therapeutics was founded by Sanjaya Singh, and the CEO is Adam Rosenberg. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Marian Nakada
| Unternehmen | Position | Ende |
|---|---|---|
Artizan Biosciences, Inc.
 Artizan Biosciences, Inc. Medical/Nursing ServicesHealth Services Artizan Biosciences, Inc. engages in the provision of healthcare services. It develops curative treatments for inflammatory diseases. The company was founded by Richard A. Flavell, Noah W. Palm and Marcel R. de Zoete and is headquartered in New Haven, CT. | Direktor/Vorstandsmitglied | 01.09.2021 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░ ░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Marian Nakada
| Harvard University | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Navitor Pharmaceuticals, Inc.
Navitor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA. | Health Technology |
ONL Therapeutics, Inc.
ONL Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ONL Therapeutics, Inc. develops biopharmaceutical services. It protects and improves the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration. The company was founded by David Zacks and Jeffery Jamison in 2006 and is headquartered in Ann Arbor, MI. | Health Technology |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Finance |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | Commercial Services |
| Centocor Johnson & Johnson | |
Vascular Pharmaceuticals, Inc.
Vascular Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vascular Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of diabetics. It provides new treatment options to individuals living with diabetic complications such as nephropathy. The company was founded by David R. Clemmons and Laura Maile in 2005 and is headquartered in Research Triangle Park, NC. | Health Technology |
Janssen, Inc.
 Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | Health Technology |
CoStim Pharmaceuticals, Inc.
 CoStim Pharmaceuticals, Inc. BiotechnologyHealth Technology CoStim Pharmaceuticals, Inc. operates as a biotech company which develops biologics for oncology indications. It offers therapies which target immune checkpoint inhibitors for novel treatment. The company was founded on February 01, 2013 and is headquartered in Boston, MA. | Health Technology |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA. | Health Technology |
Artizan Biosciences, Inc.
Artizan Biosciences, Inc. Medical/Nursing ServicesHealth Services Artizan Biosciences, Inc. engages in the provision of healthcare services. It develops curative treatments for inflammatory diseases. The company was founded by Richard A. Flavell, Noah W. Palm and Marcel R. de Zoete and is headquartered in New Haven, CT. | Health Services |
Redona Therapeutics, Inc.
 Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA. | Health Technology |
Aliada Therapeutics, Inc.
Aliada Therapeutics, Inc. BiotechnologyHealth Technology Aliada Therapeutics, Inc. is a neuroscience-focused company that aims to overcome the delivery hurdle in large molecule drug development. The company is based in Boston, MA. The company is advancing a generation of CNS therapeutics using its novel BBB crossing platform technology, which can efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness. Aliada Therapeutics was founded by Sanjaya Singh, and the CEO is Adam Rosenberg. | Health Technology |
